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The mechanisms that promote an inflammatory environment and
accelerated atherosclerosis in diabetes are poorly understood.
We show that macrophages isolated from two different mouse
models of type 1 diabetes exhibit an inflammatory phenotype.
This inflammatory phenotype associates with increased expres-
sion of long-chain acyl-CoA synthetase 1 (ACSL1), an enzyme that
catalyzes the thioesterification of fatty acids. Monocytes from
humans and mice with type 1 diabetes also exhibit increased
ACSL1. Furthermore, myeloid-selective deletion of ACSL1 protects
monocytes and macrophages from the inflammatory effects of
diabetes. Strikingly, myeloid-selective deletion of ACSL1 also pre-
vents accelerated atherosclerosis in diabetic mice without affecting
lesions in nondiabetic mice. Our observations indicate that ACSL1
plays a critical role by promoting the inflammatory phenotype of
macrophages associated with type 1 diabetes; they also raise the
possibilities that diabetic atherosclerosis has an etiology that is, at
least in part, distinct from the etiology of nondiabetic vascular
disease and that this difference is because of increased monocyte
and macrophage ACSL1 expression.
It is becoming increasingly clear that monocytes isolated fromhumans with type 1 diabetes display an inflammatory phenotype
and secrete higher levels of proinflammatory cytokines, such as
IL-6 and IL-1β, than do monocytes from subjects without diabetes
(1–5). Furthermore, inflammatory monocytes found in the setting
of type 1 diabetes have recently been shown to result in Th17 cell
activation (2, 6), suggesting that the proinflammatory effect of
diabetes on monocytes/macrophages may result in wide-ranging
effects on the immune system. Monocytes and macrophages are
centrally important in atherogenesis and may play critical roles in
diabetes-accelerated cardiovascular disease (7) and other com-
plications of diabetes. Atherosclerotic vascular disease is the
leading cause of death among people with types 1 and 2 diabetes,
but this greatly increased incidence cannot be completely
explained by the traditional cardiovascular risk factors. Systemic
factors, such as dyslipidemia, hyperglycemia, hypertension, micro-
albuminuria, and low-grade inflammation, are often viewed as
culprits in diabetic vascular disease. For example, clinical studies
suggest that suboptimal glycemic control early in the cardiovas-
cular disease progression promotes cardiovascular events later in
life in subjects with type 1 diabetes (8). This hypothesis is sup-
ported by studies on animal models of the disease (9–11).
One viewpoint that has gained increased traction is that direct
effects of diabetes on atherosclerotic lesion cells, such as macro-
phages, play an additional important role (12). Thus, the increased
macrophage expression of inflammatory mediators associated with
diabetes can be mimicked by elevated glucose concentrations in
vitro (13). In addition, fatty acids exert inflammatory effects in
macrophages, which could contribute to inflammation in the set-
ting of diabetes (14), diabetes-accelerated atherosclerosis, and
possibly other complications. After entering the cell, these fatty
acids are thioesterified into their acyl-CoA derivatives, a process
catalyzed by long-chain acyl-CoA synthetases (ACSLs).
In the current studies, we investigated the potential link be-
tween ACSL and diabetes in macrophages and monocytes. We
show that ACSL1, an enzyme that hitherto has been implicated
only in fatty acid incorporation into cellular lipids and use for
β-oxidation, is up-regulated in monocytes and macrophages
by type 1 diabetes, concomitant with well-known inflammatory
mediators. Furthermore, myeloid-targeted deletion of ACSL1
inhibits the inflammatory activation of macrophages in the set-
ting of diabetes and prevents diabetes-accelerated atheroscle-
rosis in an established mouse model of type 1 diabetes. Our
observations show that ACSL1 is centrally and selectively im-
portant in mediating the inflammatory phenotype of macro-
phages associated with diabetes.
Results
Diabetes Results in an Inflammatory Macrophage Phenotype Charac-
terized by Increased ACSL1 Expression and Increased Arachidonoyl-CoA
Levels. Monocytes isolated from human subjects with type 1 di-
abetes exhibit increased secretion of proinflammatory cytokines
(1, 2). Using a transgenic mouse model of type 1 diabetes, in which
T-cell–mediated destruction of pancreatic β-cells expressing a viral
glycoprotein (GP) can be induced at will by lymphocytic chorio-
meningitis virus (LCMV) injection (10), we investigated if diabetes
promotes a proinflammatory state in macrophages. LCMV-injec-
ted low-density lipoprotein receptor (LDLR)−/−;GP+ mice were
hyperglycemic (Fig. 1A) but showed no significant changes in
blood cholesterol (Fig. 1B) compared with saline-injected LDLR−/−;
GP+ mice or LCMV-injected LDLR−/− mice without the GP
transgene (Fig. S1 A and B). In both resident and thioglycollate-
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elicited macrophages from diabetic mice, there was a clear in-
crease in mRNA levels of inflammatory mediators, including
Il1b (Fig. 1C), Tnfa (Fig. 1D), and prostaglandin-endoperoxide
synthase 2 (Ptgs2) or cyclooxygenase 2 (Fig. 1E), compared with
macrophages from nondiabetic littermates. Additionally, con-
sistent with the elevated Ptgs2 levels, macrophages from diabetic
mice secreted increased levels of prostaglandin (PG) E2 (319.8 ±
57.4 pg/2 × 106 cells from diabetic mice vs. 179.6 ± 19.2 pg/2 ×
106 cells from nondiabetic mice, n = 4–5, P < 0.05). Conversely,
there were no significant changes in mRNA levels of the anti-
inflammatory mediator Tgfb1 (Fig. 1F). The increased macro-
phage proinflammatory status could not be explained by LCMV
injection per se (Fig. S1 C–F). Interestingly, Acsl1 mRNA was
also up-regulated in macrophages from animals with diabetes
(Fig. 1G).
To investigate if these results could be confirmed in another
model of type 1 diabetes, we analyzed thioglycollate-elicited
peritoneal macrophages from streptozotocin diabetic mice and
nondiabetic littermates. Consistent with the data on the LDLR−/−;
GP model, streptozotocin diabetic mice had elevated blood
glucose levels (Fig. 1H) without differences in blood cholesterol
levels (Fig. 1I). Furthermore, peritoneal macrophages harvested
from streptozotocin diabetic mice showed a similar increase in
Il1b, Tnfa, and Ptgs2, which associated with an increase in Acsl1
mRNA (Fig. 1 J–N). In addition, total ACSL enzymatic activity
was significantly up-regulated in macrophages from diabetic mice
(Fig. 1O), and this up-regulation resulted in a selective increase
in arachidonoyl-CoA (20:4-CoA) levels as measured by liquid
chromatography electrospray ionization tandem MS (LC-ESI-
MS/MS) (Fig. 1P). At the level of signal transduction, phos-
phorylation of JNK was increased in thioglycollate-elicited
macrophages from diabetic mice (Fig. 1Q), further supporting
the evidence of an inflammatory macrophage phenotype. Thus,
ACSL1 expression correlates with an inflammatory macrophage
phenotype and increased 20:4-CoA levels in diabetes.
Other studies have implicated ACSL1 in neutral lipid accu-
mulation in cells (15–18); however, the increased ACSL1 in
macrophages from diabetic mice was not associated with in-
creased macrophage neutral lipid loading, which was assessed by
oil red O staining (Fig. 1R).
Next, we isolated CD14+ monocytes from human subjects with
type 1 diabetes 528 ± 168 d within its onset and age-matched
controls (patients with diabetes were 28.6 ± 3.1 y and controls
were 30.2 ± 3.9 y, P = 0.74, n = 9 and n = 8, respectively). The
subjects with diabetes were on insulin therapy, but they did not
take any other medication and did not have complications of
diabetes. Although a relatively small number of matched human
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Fig. 1. Diabetes promotes an inflammatory macrophage phenotype characterized by increased ACSL1 expression. (A–G, O, and R) LDLR−/−;GP+ (n = 5–7) mice
were injected with LCMV or saline; alternatively (H–N, P, and Q), LDLR−/−;GP+ mice (n = 6–9) were injected with streptozotocin (STZ) or citrate buffer (control).
All mice were maintained on a low-fat diet for 4 wk after the onset of diabetes. At the end of 4 wk, blood glucose (A and H) and blood cholesterol (B and I)
were measured, and peritoneal macrophages were harvested by lavage. Real-time qPCR was used to determine abundance of pro- and antiinflammatory
markers. (C and J) Il1b mRNA, (D and K) Tnfa mRNA, (E and L) Ptgs2 mRNA, (F and M) Tgfb1 mRNA, and (G and N) Acsl1 mRNA. Similar results were obtained
from thioglycollate-elicited and resident macrophages. (O) Total ACSL enzymatic activity measured as the rate of conversion of [3H]-18:1 to [3H]-18:1-CoA in
thioglycollate-elicited macrophages. (P) Acyl-CoA species measured by LC-ESI-MS/MS. (Q) Phospho-JNK levels were measured by Western blot and normalized
to total levels of JNK in thioglycollate-elicited macrophages (n = 4–5). (R) Oil red O staining of thioglycollate-elicited macrophages. (S) CD14+ monocytes were
isolated from human subjects with type 1 diabetes or age-matched controls. ACSL1mRNA was measured by real-time qPCR (n = 8–9). The results are expressed
as mean + SEM or scatter plots. *P < 0.05, **P < 0.01, and ***P < 0.001 by unpaired Student t test compared with nondiabetic controls. Levels of mRNA are
expressed as fold-over nondiabetic controls. When statistically justified, mRNA levels were log-transformed before statistical analysis was performed. ND,
nondiabetic mice; D, diabetic mice; T1DM, human subjects with type 1 diabetes mellitus; C, control.
E716 | www.pnas.org/cgi/doi/10.1073/pnas.1111600109 Kanter et al.
data from the two mouse models, human subjects with type 1
diabetes had significantly elevated levels of ACSL1 mRNA in
monocytes (Fig. 1S).
In summary, diabetes induces inflammatory changes in mouse
macrophages concomitant with up-regulation of ACSL1 in the
absence of neutral lipid accumulation or changes in plasma lipid
levels. A similar up-regulation of ACSL1 is present in CD14+
monocytes from human subjects with type 1 diabetes.
ACSL1 Is Up-Regulated in Highly Inflammatory Mouse and Human
Macrophages.To investigate whether the reason for up-regulation
of ACSL1 in macrophages by diabetes could be because of in-
flammation, we used the well-established highly inflammatory
macrophage population induced by LPS and IFN-γ in vitro
(commonly referred to as M1 activation) (19). Mouse bone
marrow-derived macrophages (BMDMs) were differentiated
using macrophage colony-stimulating factor (M-CSF) and then
activated into M1 macrophages. Interestingly, ACSL1 was
markedly up-regulated in M1 macrophages compared with
unactivated controls. This up-regulation of ACSL1 was evident
at the Acsl1 mRNA level (Fig. 2A), ACSL1 protein level (P <
0.05), and plasma membrane-associated ACSL1 (Fig. 2B). IL-4
stimulation (M2 activation) did not up-regulate ACSL1 (Fig.
2B). Furthermore, insulin did not regulate ACSL1 expression in
macrophages under unactivated basal or M1 conditions (M1
stimulation resulted in a 5.5 ± 0.6-fold increase in Acsl1 mRNA
in the absence of insulin and a 5.3 ± 0.4-fold increase in the
presence of 10 nM insulin, n = 3, P = 0.74).
We next investigated whether human macrophages would
respond with an increase in ACSL1 to inflammatory conditions.
Like mouse BMDMs, human monocyte-derived macrophages
exhibited a significant increase in ACSL1 mRNA after M1
stimulation compared with unactivated controls (Fig. 2C), and
this increase was associated with a significant increase in plasma
membrane-associated ACSL1 (Fig. 2D). Inflammatory activa-
tion, therefore, up-regulates ACSL1 both in mouse and human
macrophages.
Generation of a Myeloid-Selective ACSL1-Deficient Mouse Model.We
next generated a mouse model with myeloid-specific ACSL1
deficiency (Fig. 3A), which is referred to as the ACSL1M−/−
(myeloid-selective ACSL1-deficient) mouse. Acsl1 mRNA levels
were markedly reduced in macrophages from ACSL1M−/− mice
compared with wildtypes (WTs) (Fig. 3B). ACSL1 protein
(Fig. 3C) and total ACSL enzymatic activity were significantly
reduced in ACSL1M−/− macrophage lysates (Fig. S2A) but not in
liver (Fig. S2B), showing tissue selectivity of the ACSL1 deletion.
ACSL1 is a predominant ACSL isoform in mouse macrophages
(20). The finding that ACSL1 deficiency reduced total ACSL
activity by ∼45% (Fig. S2A) suggests that other ACSL isoforms
or other enzymes with ACSL activity make up the remaining
∼55% of oleoyl-CoA synthetase activity in isolated macrophages.
Importantly, there was no compensatory up-regulation of gene
expression of other ACSL isoforms in ACSL1-deficient macro-
phages (Fig. S2 C and D). Thus, the ACSL1M−/− mouse exhibits
a marked loss of ACSL1 in macrophages.
ACSL1 Deficiency Does Not Impair Macrophage Neutral Lipid
Accumulation in Vivo. ACSL1 has been implicated in neutral
lipid accumulation (15–18) and β-oxidation pathways (21) in liver
and adipose tissue. Accordingly, ACSL1-deficient macrophages
challenged with oleate (18:1) in vitro exhibited defects in 18:1
partitioning into neutral lipids and increased levels of cellular
free 18:1, but they showed no changes in 18:1 β-oxidation
(Fig. S2 E–H). Furthermore, total cellular levels of free and
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Fig. 2. ACSL1 is markedly increased in inflammatory macrophages. Mouse
BMDMs from WT mice were activated using LPS/IFN-γ (for M1 polarization)
or IL-4 (for M2 polarization) or were left as unactivated controls for 48 h. (A)
Acsl mRNA levels were measured by real-time qPCR. (B) Plasma membranes
isolated from biotin-labeled M1 and M2 macrophages and unactivated
macrophages (controls) were subjected to LC-MS/MS. The spectral counts
represent the total number of ACSL1-derived peptides identified (n = 6). (C)
Human monocyte-derived macrophages were differentiated in the presence
of M-CSF and then activated with LPS/IFN-γ (M1) or left unactivated (control).
ACSL1 mRNA was measured by real-time qPCR (n = 3–5). (D). Membrane-
associated ACSL1 in human monocyte-derived macrophages was measured
by Western blot or LC-MS/MS as described for mouse BMDMs. The results are
expressed as mean + SEM (n = 3 unless otherwise noted). *P < 0.05 and **P <
0.01 by unpaired Student t test. C, control.
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Fig. 3. Generation of a myeloid-selective ACSL1-deficient mouse model. (A)
Acsl1 PCR yields a 763-bp band for the WT Acsl1 allele and a 319-bp band for
the LoxP allele (Upper). LysM-Cre recombinase PCR yields a 350-bp band for
the WT allele and a 700-bp band for the LysM Cre-recombinase allele. (B)
Loss of Acsl1 mRNA in thioglycollate-elicited macrophages from ACSL1M−/−
mice. (C) Reduced ACSL1 protein levels in thioglycollate-elicited peritoneal
macrophages from ACSL1M−/− mice. (D–F) Thioglycollate-elicited macro-
phages from LDLR−/− mice (n = 7–10) transplanted with bone marrow from
WT or ACSL1M−/− mice were stained with Oil red O for neutral lipids (D) or
used to quantify total cellular cholesterol (E) and total cellular triacylglycerol
(F). The results are expressed as mean + SEM (n = 3 unless otherwise noted).
**P < 0.01 by unpaired Student t test (B and C). TG, triacylglycerol.

















ACSL1 deficiency, but a significant inhibition of 18:1-induced
triacylglycerol (TG) accumulation was noted in vitro (Fig. S2 I–
K). To test whether ACSL1 deficiency reduces neutral lipid ac-
cumulation in macrophages in LDLR−/− mice, which have
a plasma lipid profile more similar to humans than C57BL/6
mice, LDLR−/− mice received bone marrow transplants from
WT or ACSL1M−/− mice. Thioglycollate-elicited macrophages
from mice transplanted with ACSL1M−/− bone marrow exhibited
the expected reduction in Acsl1 mRNA, suggesting adequate
reconstitution and chimerism. However, there were no defects in
neutral lipid accumulation in these ACSL1-deficient macro-
phages (Fig. 3 D–F).
Myeloid ACSL1 Deficiency Reduces Arachidonoyl-CoA Levels and Inflam-
matory PGE2 Secretion from Macrophages Under High-Glucose Condi-
tions.We further investigated the cellular consequences of ACSL1
deficiency. ACSL1 deficiency resulted in a marked reduction in
20:4-CoA levels, whereas other acyl-CoA species were not signif-
icantly affected (Fig. 4A), consistent with the increased ACSL1
and increased 20:4-CoA levels in macrophages from diabetic mice
(Fig. 1P). We next evaluated the effect of ACSL1 deficiency on
arachidonic acid-derived lipid mediators (and some lipid media-
tors derived from other long-chain fatty acids) in macrophages
subjected to normal (5.5 mM) or high (25 mM) glucose conditions
by using LC-MS/MS. Macrophages differentiated in the presence
of a high-glucose concentration exhibited elevated levels of PGE2
and PGD2 (Fig. 4B and Table S1). Interestingly, ACSL1 deficiency
slightly but significantly blunted the increased PGE2 and PGD2
production in inflammatory macrophages subjected to high-glu-
cose concentrations but not macrophages maintained in normal
glucose (Fig. 4B and Table S1). Elevated glucose also resulted in
increased levels of 15-HETE, 17-HDHA, and PGF2α, but ACSL1
deficiency had no effect on these lipid mediators or other lipid
mediators under the conditions tested (Table S1).
To investigate whether the increased PGE2 or PGD2 levels
might exert inflammatory actions in macrophages, BMDMs were
differentiated in the presence or absence of 5 μM PGD2 or
PGE2. Exogenously added PGD2 had less of an inflammatory
effect than PGE2. Thus, we focused our subsequent studies on
PGE2. Indeed, exogenous PGE2 stimulated IL-6 release, and this
effect was enhanced under high-glucose conditions (Fig. 4C),
possibly because of the increased endogenous PGE2 production
in glucose-stimulated cells.
To better understand the mechanism whereby high-glucose
concentrations can stimulate PGE2 production in macrophages,
we analyzed mRNA levels of enzymes in the PGE2 synthesis
pathway. Elevated glucose promoted Ptgs2 mRNA levels in M1
macrophages (Fig. 4D), consistent with data on macrophages
from diabetic mice (Fig. 1 E and L). Similar results were
obtained for microsomal PtgesmRNA (Fig. 4E), which in concert
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Fig. 4. ACSL1 deficiency inhibits arachidonoyl-CoA synthesis and levels of inflammatory PGE2, cytokines, and chemokines in macrophages. (A) Acyl-CoA levels
in thioglycollate-elicited macrophages were measured by LC-ESI-MS/MS (n = 8). (B) Levels of 20:4-derived PGE2 (n = 4–5). (C) IL-6 release, measured by ELISA,
from unactivated BMDMs differentiated in the presence or absence (control vehicle) or 5 μM PGE2 and 25 or 5 mM D-glucose (n = 3). (D and E) Ptgs2 and Ptges
levels in WT M1 and M2 BMDMs under normal (5.5 mM) and high (25 mM)-glucose conditions were measured by real-time qPCR (n = 3). (F–K) Diabetes was
induced in WT and ACSL1M−/− mice by streptozotocin (n = 3–5). After 4 wk of diabetes, thioglycollate-elicited macrophages were isolated, adhesion-purified
for 1 h, and then incubated in the presence of 5 ng/mL LPS or 5% autologous serum for 6 h as indicated, or WT and ACSL1M−/− macrophages from diabetic
mice were incubated in the presence of the PTGS2 inhibitor CAY10404 (500 nM) or vehicle (L–N). PGE2 release (F and G), IL-1β release (H and M), IL-6 release
(I and J), CCL2 release (K and N), and TNF-α release (L) were measured by ELISA. IL-1β and CCL2 release from serum-stimulated cells was below detection or
100-fold lower than in LPS-stimulated cells. (O–Q) Freshly isolated nonstimulated monocytes were isolated from blood of nondiabetic and diabetic WT
and ACSL1M−/− mice after 4 wk of induction of diabetes with streptozotocin. Acsl1 (O), Tnfa (P), and Il6 (Q) mRNA was measured by real-time PCR. The results
are expressed as mean + SEM (n = 3–4 unless otherwise noted). *P < 0.05, **P < 0.01, and ***P < 0.001; ANOVA.
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with PTGS2, promotes production of PGE2 from 20:4. Other
enzymes involved in eicosanoid production, such as arachidonate
5- and 15-lipoxygenases or thromboxane A synthetase 1, were
not elevated by glucose in M1 macrophages, but arachidonate 5-
lipoxygenase was markedly elevated by glucose in M2 macro-
phages (Fig. S3); 19.5 mM L-glucose, used as an osmotic control,
did not mimic the effect of high glucose (Fig. S3). Finally,
ACSL1 deficiency did not affect peroxisome proliferator-acti-
vated receptors or liver X receptor target genes (Fig. S3), in-
dicating that increased activity of these nuclear receptors cannot
explain the effect of ACSL1 deficiency.
Together, these results suggest that increased 20:4-CoA levels,
as a result of ACSL1 induction, and subsequent release of PGE2
from macrophages in the setting of diabetes contribute to the
diabetes augmented inflammatory macrophage phenotype.
Myeloid-Specific ACSL1 Deficiency Selectively Prevents the Inflam-
matory Phenotype of Macrophages from Diabetic Mice and Diabetes-
Accelerated Atherosclerosis. Because ACSL1 expression correlates
with an inflammatory macrophage phenotype in the setting of
diabetes, we next investigated whether ACSL1 modulates the in-
flammatory response. Diabetes was induced in WT and ACSL1M−/−
mice by streptozotocin, and 4 wk later, thioglycollate-elicited mac-
rophages were collected, adhesion-purified, and incubated in the
presence of 5% autologous serum or 5 ng/mL LPS for 6 h. Con-
sistent with our findings in the LDLR−/−;GP+ model, macro-
phages from diabetic mice released more PGE2 than macrophages
from nondiabetic mice, both under autologous serum and LPS
stimulations, and this effect was completely prevented by ACSL1
deficiency (Fig. 4 F and G), consistent with the in vitro data (Fig.
4B), although the in vivo effect of ACSL1 deficiency was more
marked. Diabetes also resulted in increased release of IL-1β, IL-6,
chemokine (C-C motif) ligand 2 (CCL2), and TNF-α from mac-
rophages. ACSL1 deficiency completely prevented the effect of
diabetes on release of cytokines but had no effect in macrophages
from nondiabetic mice (Fig. 4 H–K). Similarly, albeit less striking,
ACSL1 deficiency reduced release of cytokines from M1 macro-
phages in vitro without affecting the M2 activation marker argi-
nase 1 (Table 1). Thus, the in vitro M1 activation model does not
exactly mimic the effect of diabetes on macrophages.
Together, these results suggest that ACSL1 deficiency prevents
release of an inflammatory 20:4-derived lipid mediator under di-
abetic conditions. To directly test this hypothesis, thioglycollate-
elicited macrophages were harvested from diabetic WT and
ACSL1M−/−mice and incubated with LPS as above in the presence
or absence of a selective PTGS2 inhibitor CAY10404 (500 nM).
Inhibition of PTGS2 significantly reduced the production of TNF-
α, IL-1β, and CCL2 in WT diabetic macrophage but had no effect
on diabetic ACSL1-deficient macrophages (Fig. 4 L–N).
In addition, freshly isolated nonstimulated monocytes from
diabetic animals displayed increased Acsl1 expression and in-
flammatory markers (Fig. 4 O–Q), similar to what was observed
in monocytes from humans with type 1 diabetes (Fig. 1S) (1–2).
This display showed that the effect of diabetes on myeloid
ACSL1 induction is not limited to peritoneal macrophages but
occurs at the level of the circulating monocyte, and it is main-
tained as these monocytes differentiate into macrophages. In-
terestingly, ACSL1 deficiency prevented the diabetes-induced
up-regulation of Tnfa and Il6 mRNA in monocytes. These results
show that ACSL1-deficient monocytes/macrophages have a
markedly impaired inflammatory capacity in the setting of diabetes.
To elucidate the role of macrophage ACSL1 deficiency in di-
abetes-accelerated atherosclerosis, we next transplanted LDLR−/−;
GP+ mice with bone marrow from WT or ACSL1M−/− mice.
Diabetic mice fed the low-fat diet previously used in this model
(10) were hyperglycemic (Fig. 5A) but showed no significant
differences in blood cholesterol levels (Fig. 5B) during the 12-wk
study or plasma TG levels at the end of the study (Fig. 5C)
compared with nondiabetic controls, consistent with our previous
studies (10). Importantly, myeloid ACSL1 deficiency did not in-
terfere with the onset or severity of diabetes (Fig. 5A), and it did
not affect blood glucose, cholesterol, plasma triglycerides, or
nonesterified fatty acids in diabetic or nondiabetic mice (Fig. 5
A–C and Table S2). There also were no statistically significant
differences in markers of systemic inflammation between the four
groups (Table S2), and no differences were observed in monocyte
numbers or markers for neutrophils (S100a8) or monocyte Ly6hi
and Ly6lo subsets in blood from WT and ACSL1M−/− mice
(Fig. S3), suggesting that ACSL1 deficiency did not reduce the
number of circulating monocytes or neutrophils in nondiabetic or
diabetic mice. Acsl1 mRNA levels were barely detectable in WT
peritoneal neutrophils and not reduced in neutrophils from
ACSL1M−/− mice (Fig. S3K). Furthermore, ACSL1 deficiency did
not induce apoptosis in macrophages from nondiabetic or
diabetic mice (Fig. S4A).
Peritoneal macrophages were harvested from a subset of bone
marrow-transplanted mice 4 wk after induction of diabetes for
investigation of the extent of chimerism and the proinflammatory
phenotype of macrophages. As shown in Fig. 5D, diabetes in-
creased Acsl1 mRNA in macrophages from WT diabetic mice
compared with WT nondiabetic mice, which was expected. Mice
that had received bone marrow from ACSL1M−/− mice exhibited
an almost complete loss of Acsl1 mRNA and ACSL1 protein in
macrophages, showing efficient chimerism. Macrophages de-
ficient in ACSL1 were protected from diabetes-induced release
of CCL2 (Fig. 5E) and TNF-α (Fig. 5F) also in this model of
diabetes, consistent with the data in Fig. 4 H–K.
Because macrophages play a critical role in diabetes-acceler-
ated atherosclerosis (10), formation of macrophage-rich lesions
was next used as a biological endpoint to investigate the pro-
tective effect of ACSL1 deficiency in macrophages in the setting
of diabetes. Analysis of Movat’s pentachrome-stained cross-sec-
tions of atherosclerotic lesions in the brachiocephalic artery
(BCA) revealed that diabetes increased lesion size (Fig. 5 G–I),
as previously described (10). Interestingly, myeloid ACSL1 de-
ficiency prevented diabetes-accelerated atherosclerosis (Fig. 5
G–I) by reducing macrophage accumulation (Fig. 5 H and J).
However, macrophage ACSL1 deficiency did not reduce the le-
sion area or macrophage accumulation in nondiabetic mice
(Fig. 5 G–J). Similar results were obtained from Sudan IV-
stained aortic arches, where the lesions were larger than in the
BCA (Fig. 5K). We next evaluated PTGS2 and CCL2 immuno-
reactivity in BCA lesions from the four groups of mice. Lesion
PTGS2 immunoreactivity was weak but specific, and it was
observed in macrophage areas (Fig. 5L). Lesions from diabetic
WT mice exhibited more PTGS2-positive cells compared with
nondiabetic mice (P < 0.05), whereas there was no difference
between nondiabetic mice and diabetic ACSL1M−/− mice. Specific
CCL2 immunoreactivity was detectable in macrophage-rich areas,
although not all macrophages stained positive for CCL2 (Fig. 5M).
Fewer diabetic ACSL1M−/− mice showed CCL2-positive lesions
compared with WT diabetic mice (P < 0.05, Fisher exact test).
Table 1. MyeloidACSL1deficiency inhibits releaseof inflammatory
mediators from LPS/IFNγ-stimulated (M1) macrophages
WT ACSL1M−/−
IL-6 (ng/μg protein) 124.0 ± 0.6 58.5 ± 9.0*
TNF-α (ng/μg protein) 65.8 ± 4.1 33.0 ± 7.1†
CCL2 (ng/μg protein) 336.7 ± 17.0 262.2 ± 17.0†
Arginase 1 (arbitrary units) 0.92 ± 0.2 0.94 ± 0.1
Mean ± SEM (n = 3–6).
*P < 0.01 by unpaired Student t test.
†P < 0.05 by unpaired Student t test.

















To confirm that the selective protection provided by myeloid
ACSL1 deficiency in diabetic mice was not because of the fact
that lesions were larger in diabetic than nondiabetic mice, a group
of nondiabetic mice transplanted with WT or ACSL1M−/− bone
marrow were analyzed after 20 wk. The atherosclerotic lesions in
these nondiabetic mice were of the same size as the lesions in
diabetic mice at the 12-wk time point. Myeloid ACSL1 deficiency
did not reduce the size of these larger lesions in nondiabetic mice
(Fig. S4B), showing that myeloid ACSL1 deficiency selectively
prevents atherosclerosis in the diabetic setting. Furthermore,
myeloid ACSL1 deficiency did not reduce lesion size in hyper-
lipidemic nondiabetic LDLR−/− mice fed a high-fat diet (Fig. S4).
To investigate whether myeloid ACSL1 expression plays a role
in advanced preexisting lesions, LDLR−/−;GP+ mice were fed
a semipurified high-fat diet for 16 wk (22) to allow advanced
lesions to develop in the BCA. The mice were then switched to
the low fat diet used above, transplanted with bone marrow from
WT or ACSL1M−/− mice, injected with LCMV or saline after
a recovery period, and maintained on the low fat diet for another
12 wk. Diabetes did not alter plasma lipid levels or lesion se-
verity, consistent with our previous studies on this model in
which diabetes had a detrimental effect on preexisting advanced
lesions only when it was associated with elevated triglycerides
(22). Diabetic mice with myeloid ACSL1 deficiency exhibited
a small but significant reduction in the overall lesion severity
using a combination of markers (Table S3), in these preexisting
fibrotic advanced lesions (Fig. S4). However, this effect was small
compared with the effect of myeloid ACSL1 deficiency on
macrophage accumulation in early lesions in the setting of di-
abetes, perhaps because macrophages constituted only <10% of
these advanced lesions.
Discussion
We show that type 1 diabetes, both in mouse models of the
disease and human subjects, results in increased levels of ACSL1
in monocytes and macrophages. This increase in ACSL1 ex-
pression is associated with increased levels of 20:4-CoA and an
increased PGE2 release from macrophages from diabetic mice.
We also show that inhibition of PTGS2 blocks the inflammatory
macrophage phenotype associated with diabetes, showing that
the inflammatory effect of diabetes is because of a PTGS2-
derived lipid mediator. Of the lipid mediators analyzed in this
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Fig. 5. Myeloid ACSL1 deficiency protects against the diabetes-induced macrophage inflammatory phenotype and atherosclerosis. Female LDLR−/−;GP+ mice
(12–14 wk) were bone marrow-transplanted with bone marrow from WT or ACSL1M−/− mice. After a 3- to 7-wk recovery period, diabetes was induced. The
mice were maintained on a low-fat diet after the onset of diabetes. Blood glucose (A) and cholesterol (B) were monitored at indicated time points, and
plasma TG (C) was measured at the end of the 12-wk study (n = 8–15). A subset (n = 5–7) of mice was euthanized after 4 wk of diabetes, and thioglycollate-
elicited peritoneal macrophages were harvested by lavage. Real-time qPCR was used to determine abundance of (D) Acsl1 mRNA, and Western blot was used
to detect ACSL1 protein. ELISAs were used to determine levels of secreted CCL2 (E) and TNF-α (F) in the media after a 6-h incubation. After 12 wk of diabetes,
the entire BCA was serial-sectioned. (G) Examples of Movat’s pentachrome-stained cross-sections of the BCA. (H) Sections from diabetic animals stained using
an anti–Mac-2 antibody. (I) The macrophage-rich lesion area was analyzed over three slides at the site of maximal lesion size for each mouse. (J) Quantifi-
cation of Mac-2–positive lesion BCA area. (K) The aorta was opened longitudinally, the aortic arch was stained using Sudan IV, and the Sudan IV-positive
lesion area was quantified by Image J. (L) Immunohistochemistry showing PTGS2 immunoreactivity in lesions from diabetic mice and an isotype-matched
negative control antibody. (M) Immunohistochemistry showing CCL2 immunoreactivity in lesions from diabetic mice. The results are expressed as mean +
SEM. *P < 0.05 and ***P < 0.001 by one-way ANOVA. (Scale bar: 100 μm.) The results are shown as mean + or ± SEM. *P < 0.05 and ***P < 0.001 by one-way
ANOVA or Student t test (F).
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study, PGE2 was identified as the most likely candidate, although
we cannot rule out contribution of other PTGS2 products. Thus,
PGE2 promotes an inflammatory phenotype of mouse macro-
phages when these cells are exposed to PGE2 during differenti-
ation, consistent with recent findings in human macrophages
(23). This long-term inflammatory effect of PGE2 is different
from its ability to acutely inhibit LPS-induced inflammation
through EP4 receptor-associated protein (24).
Conversely, myeloid-specific ACSL1 deficiency results in
a specific reduction in 20:4-CoA levels and completely prevents
the increased release of PGE2 and increased inflammatory
phenotype in monocytes and macrophages from diabetic mice,
showing that the increased ACSL1 expression is required for
diabetes-stimulated PGE2 release and release of inflammatory
chemokines and cytokines. Furthermore, whereas PTGS2 inhibition
completely blocks the inflammatory phenotype of macrophages
from diabetic mice, such inhibition has no effect in ACSL1-de-
ficient macrophages, supporting the conclusion that ACSL1 de-
ficiency acts by reducing the PTGS2 pathway. Myeloid ACSL1
deficiency prevents the diabetes-accelerated macrophage accu-
mulation in lesions of atherosclerosis. The selectivity of the pro-
tective effect of myeloid ACSL1 deficiency suggests that induction
of a macrophage inflammatory phenotype and atherosclerosis in
the setting of diabetes has an etiology that may be different from
the etiology of atherosclerosis in the absence of diabetes and that
one of the differences is an increased ACSL1 expression in my-
eloid cells. Our observations indicate that the inhibitory effect of
ACSL1 deficiency on the inflammatory phenotype of macro-
phages associated with diabetes is likely to explain its anti-
atherosclerotic effects in diabetic mice and suggest that diabetes-
accelerated atherosclerosis might be driven by an increased in-
flammatory phenotype characterized by increased ACSL1 ex-
pression in myeloid cells. Importantly, these studies identify a key
step in the mechanism of diabetes-induced macrophage in-
flammatory changes and atherosclerosis.
The reduced macrophage accumulation in diabetic mice with
myeloid ACSL1 deficiency is unlikely to be because of increased
macrophage neutral lipid loading, because no defect in lipid
accumulation was observed in ACSL1-deficient macrophages.
Thus, myeloid-specific ACSL1 deletion in vivo is unlikely to
promote cholesterol efflux, which has been shown in fatty acid-
loaded macrophages in vitro (25) and results in a more specific
effect than systemic inhibition of several of the ACSL isoforms
using triacsin C (26). Increased macrophage death in the absence
of ACSL1 is also unlikely to explain the phenotype, because no
increase in macrophage apoptosis is observed in ACSL1-de-
ficient macrophages. Furthermore, we have previously shown
that, in this mouse model, macrophage proliferation within the
atherosclerotic lesion is nondetectable (27), indicating that
macrophage ACSL1 deficiency is unlikely to act through a re-
duced macrophage proliferation. Thus, the reduced lesion
macrophage accumulation in mice with ACSL1-deficient mac-
rophages is most likely because of reduced recruitment of
monocytes into the lesion. Our findings that CCL2 secretion is
increased from macrophages from diabetic mice and that this
effect is completely prevented by ACSL1 deficiency, together
with the findings that ACSL1 is up-regulated in circulating
monocytes and that ACSL1 deficiency prevents diabetes-induced
inflammatory changes in monocytes, support the notion that
monocyte recruitment is reduced by ACSL1 deficiency. Fur-
thermore, CCL2 immunoreactivity was reduced by myeloid
ACSL1 deficiency in lesions of atherosclerosis in diabetic mice.
Indeed, mice deficient in CCL2 exhibit reduced atherosclerosis
concomitant with reduced lesion macrophage accumulation (28),
consistent with an important role for CCL2 in atherogenesis.
What are the molecular mechanisms of the protective effects
of ACSL1 deficiency on the monocyte and macrophage in the
diabetic milieu? Together, our results suggest that increased
release of PGE2, perhaps in combination with other inflamma-
tory 20:4-derived lipid mediators, from monocytes/macrophages
in the setting of diabetes is likely to contribute to the augmented
inflammatory phenotype. Increased release of PGE2 has been
reported previously in several cell types in response to diabetes
or elevated glucose concentrations (29–31), and it has been
shown to be caused by increased activity of calcium-dependent
phospholipase A2, which catalyzes the release of arachidonic
acid from membrane phospholipids (30) and increases PTGS2
expression (4, 31). Our studies show that, in concert with PTGS2,
prostaglandin E synthase-1 (PGES-1 or Ptges) is increased in
macrophages exposed to elevated glucose concentrations, which
is likely to contribute to the increased PGE2 synthesis seen in
macrophages from diabetic mice and macrophages exposed to
elevated glucose. Indeed, an integrated omics analysis of eico-
sanoids and their enzymes has shown that levels of PTGS2,
PGES-1, and PGE2 are preferentially increased by inflammatory
stimuli in macrophages (32), providing a likely explanation for
why elevated glucose levels promote this arm of eicosanoid
metabolism. There is also evidence supporting a proathero-
sclerotic effect of PGE2. PGES-1–deficient mice exhibit reduced
atherosclerosis and reduced macrophage accumulation in these
lesions (33). These mice have significantly reduced levels of
PGE2 but also increased levels of PGI2, which might have con-
tributed to the atheroprotective phenotype (33).
ACSL1 deficiency, with its preferential inhibitory effect on
arachidonoyl-CoA synthesis, is well-positioned to prevent di-
abetes-induced production of arachidonoyl-CoA and PGE2. The
reduced synthesis of arachidonoyl-CoA in ACSL1-deficient
macrophages likely leads to reduced trapping of free 20:4 as
arachidonoyl-CoA, resulting in a reduced pool of membrane
20:4 available as a substrate for calcium-dependent phospholi-
pase A2 and subsequent generation of PGE2 resulting from the
increased PGES-1 in macrophages exposed to elevated glucose.
Such a model is consistent with our recent studies in other tis-
sues (21, 34). However, we cannot rule out the possibility that
ACSL1 deficiency acts in part by additional mechanisms related
to the reduced synthesis of arachidonoyl-CoA or less likely,
other acyl-CoAs.
Interestingly, a recent study shows that deleting toll-like re-
ceptor 2 (TLR2) prevents the inflammatory effects of diabetes on
macrophages (35). In that study, whole-body TLR2 deficiency
reduced increased systemic inflammation in diabetic mice, which
could explain the effect on the macrophage inflammatory phe-
notype. In the present study, myeloid ACSL1 deficiency did not
affect systemic inflammation, suggesting that the mechanisms of
the reduced macrophage inflammatory phenotype in myeloid
ACSL1-deficient mice and whole-body TLR2-deficient mice might
be distinct. Nevertheless, a possible connection between ACSL1
and TLR2 signaling is an important topic for future research.
In summary, we show that diabetes results in an inflammatory
monocyte/macrophage phenotype characterized by increased
ACSL1 expression, PGE2 release, and increased chemokine and
cytokine production and that ACSL1 is critically important in
mediating the increased macrophage inflammatory phenotype
and atherosclerosis in diabetes. Our observations, thus, suggest
a model for selective inhibition of atherosclerosis associated
with diabetes.
Materials and Methods
Isolation of Monocytes, Macrophages, and Neutrophils from Nondiabetic and
Diabetic Mice. The model of type 1 diabetes (LDLR−/−;GP+), in which diabetes
can be induced at will using viral mimicry with LCMV, has been described
previously (10). Adult 12- to 14-wk-old female and male LDLR−/−;GP+ or
LDLR−/− mice without the GP transgene were injected with LCMV (1 × 105
pfu) or saline (control). One week after injection, at the onset of diabetes,
the mice were switched to a low fat semipurified diet (10) and maintained
for 4 wk. Only mice injected with LCMV and expressing the GP transgene

















become diabetic. In other experiments, diabetes was induced by strepto-
zotocin (mixed anomers no. S0130, 50 mg/kg; Sigma) dissolved immediately
before use in freshly made citrate buffer (0.1 M, pH 4.5) and injected in-
traperitoneally for 5 consecutive d in male or female adult LDLR−/−;GP mice
or WT and ACSL1M−/− mice. If mice had not developed diabetes within 2 wk
after the last injection, they were reinjected for another 5 d. Mice were
considered diabetic if their blood glucose was 250 mg/dL or higher. One
week after the last injection, the mice were switched to the low fat semi-
purified diet (10) and maintained for 4 wk. Diabetic mice were monitored at
least biweekly for glucose, glycosuria, ketonuria, and body weight. Most
LCMV-injected diabetic mice required exogenous insulin (bovine insulin
implants, Lin Shin, Toronto, ON, or Lantus, Sanofi; Aventis) to prevent
weight loss and ketonuria. At the end of 4 wk, thioglycollate-elicited, resi-
dent macrophages or monocytes were harvested as described below. In
some experiments, the macrophages were stimulated for 6 h with LPS (5 ng/
mL), autologous serum (5%), or CAY10404 (500 nM; Cayman Chemical) after
isolation and a 1-h adhesion purification. Monocytes were freshly harvested
from EDTA-collected blood, and erythrocytes were lysed followed by
monocyte enrichment using the EasySep Mouse Monocyte Enrichment kit
(Stemcell Technologies).
We initially used resident peritoneal macrophages to study the effects of
diabetes to avoid the possibility that thioglycollate might mask the effects of
diabetes (Fig. 1 C–G). Thioglycollate was later determined to not mask the
effects of diabetes on inflammatory mediators and ACSL1, and thio-
glycollate-elicited macrophages were, therefore, used in all subsequent
experiments because of the better yield of cells. Thioglycollate-elicited mac-
rophages were isolated as described previously (20). Resident peritoneal mac-
rophages were collected in the absence of thioglycollate injection. The
macrophages were adherence-purified for 1 h followed by awashwith PBS to
remove nonadherent cells. BMDM polarization to M1 and M2 states was
performed according to the work by Odegaard et al. (19). For studies of the
effect of glucose, bone marrow differentiation and activation were done in
glucose-free RPMI supplemented with either 5.5 (normal) or 25 mM (high)
endotoxin-free D-glucose or 5.5 mM D-glucose plus 19.5 mM L-glucose (Sigma
Aldrich). During the activation, media were changed every 12 h to prevent
glucose depletion.
Peritoneal neutrophils were isolated 4 h after thioglycollate injection (36).
The cells were adhesion-purified, and the nonadherent cells were used for
analysis of Acsl1 mRNA levels. RNA extraction was carried out using the
RNeasy Lipid Tissue kit (Qiagen).
Isolation of Monocytes from Human Subjects With and Without Type 1 Diabetes
and Generation of Monocyte-Derived Macrophages. To investigate levels of
ACSL1 mRNA in monocytes from human subjects with type 1 diabetes and
age-matched controls, fresh peripheral blood mononuclear cells were iso-
lated from whole-blood samples using standard Ficoll gradients. Samples
were obtained, with informed consent, from eight control and nine type
1 diabetic patients within 5 y of diagnosis through the Juvenile Diabetes
Research Fund Center for Translational Research at the Benaroya Research
Institute. Approval for these studies was obtained from the Institutional
Review Board at Virginia Mason Medical Center. CD14+ monocytes were
isolated from the peripheral blood mononuclear cells using two different
methods. Monocytes in some cases were isolated with single-cell sorting
using a FACSVantage cell sorter (BD Immunocytometry Systems). In other
cases, monocytes were isolated by positive selection using Miltenyi anti-
CD14 microbeads (Miltenyi Biotec). Representative samples from those latter
isolations were verified for CD14+ content by FACS analysis. Samples were
kept at 4 °C throughout the isolation procedures and then immediately
harvested for RNA analysis.
Peripheral blood monocytes from healthy volunteers were isolated and
differentiated into unactivated macrophages (controls) or classically acti-
vated macrophages (M1) essentially as described in the work by Martinez
et al. (37). Briefly, monocytes were obtained from normal blood donor buffy
coats by two-step gradient centrifugation followed by an additional step us-
ing CD14 positive selection on the Automacs. Macrophages were obtained by
culturing monocytes for 7 d in RPMI 1640 (HyClone) supplemented with 10%
FBS (Cellgro) and 100 ng/mL human recombinant M-CSF (R&D Systems).
Classical activation of macrophages was achieved by treating the cells with LPS
(100 ng/mL; InvivoGen) and human IFN-γ (20 ng/mL; R&D Systems) for 18 h.
Generation of Mice with ACSL1-Deficient Myeloid Cells (ACSL1M−/− Mice). Mice
with myeloid-specific ACSL1 deficiency (ACSL1M−/− mice) were generated by
interbreeding mice with the Acsl1 exon 2 flanked by LoxP sites (Acsl1flox mice)
(21) with mice expressing Cre recombinase under control of the Lysozyme M
(LysM) promoter. Acsl1flox mice were backcrossed 10 generations onto the
C57BL/6 background. LysM Cre-recombinase mice [B6.129P2-Lyz2tm1(cre)Ifo/J]
were obtained from Jackson Laboratory and further backcrossed until the
10th generation on C57BL/6. Acsl1flox mice were bred with LysM-Cre mice to
homozygozity (Acsl1flox/floxCreTg/Tg; ACSL1M−/−). Pups were born at an
expected Mendelian ratio. Several different controls were used, including
mice without floxed Acsl1 alleles (Acsl1wt/wtCre0/0 and Acsl1wt/wtCreTg/Tg) and
mice with floxed Acsl1 alleles (Acsl1flox/floxCre0/0). The loxP sites had no effect
on Acsl1 expression in the absence of Cre recombinase. To avoid the possi-
bility that results could be influenced by Cre recombinase-induced toxicity,
Acsl1wt/wtCreTg/Tg mice were used as WT controls. ACSL1M−/− mice showed no
increased mortality, gained weight normally, and exhibited no differences in
general appearance or behavior.
Genotyping. For genotyping, duplex PCR was performed on tail biopsies to
distinguish WT and Acsl1 flox alleles with WT-specific primers (forward 5′-
AGCAAGCCACATGAAGGCATGTGTG-3′, reverse 5′-AAGTGGGGGACATAGGT-
GCCACT-3′) and LoxP-specific primers (forward 5′-TAGAAAGTATAGGAAC-
TTCGGCGCG-3′, reverse 5′-GCCCCTATATCACTTTTGGCGACA-3′). The resulting
WT fragment is 763 bp, and the LoxP fragment is 391 bp. LysM-Cre recombi-
nase and WT fragments were detected using primer sequences provided by
Jackson Labs (oIMR3066-3068). The WT fragment is 350 bp, and the mutant
fragment is ∼700 bp.
Analysis of ACSL Activity, Acyl-CoAs, Neutral Lipids, and Lipid Mediators. ACSL
enzymatic activity and long-chain acyl-CoAs were measured as described
previously (20, 34). The ACSL activity assay is not specific to the ACSL1 iso-
form, and it uses [3H]-18:1 or [3H]-16:0 rather than [3H]-20:4 to avoid artifacts
caused by fatty acid oxidation. Analysis of neutral lipids is described in SI
Materials and Methods.
ELISAs, Apoptosis Assay, and Real-Time Quantitative PCR. IL-6, IL-1β, TNF-α,
and CCL2 were measured in media from mouse macrophages using ELISA
(eBioscience). PGE2 was quantified using an ELISA from Cayman Chemical.
Plasma SAA was analyzed by ELISA as previously described (38). For the
noncommercially available serum amyloid A (SAA) ELISA, anti-mouse SAA
(R&D Systems) was used. Apoptosis was evaluated by TUNEL using the HT
titer TACS kit from Trevigen.
Total RNA was isolated using Qiagen RNeasy Mini Kits. To remove trace
genomic DNA, all samples were DNase-treated. Real-time quantitative PCR
(qPCR) was run in a 20-μL reaction using SYBR Green PCRMaster Mix (Applied
Biosystems or Fermentas) either as a one-step reaction or with a separate
reverse transcription step. One-step qPCR (10 μL 2× Master Mix, 400 nM each
primer, 1.0 unit Fermentas M-MuLV reverse transcriptase (RT), 0.5 unit
RiboLock RNase Inhibitor) was run with PCR cycling conditions of 48 °C for 30
min, 95 °C for 10 min, and 40 cycles of 95 °C for 15 s and 60 °C for 1 min.
After each assay, a dissociation curve was run to confirm specificity of all PCR
amplicons. All primer reactions were also analyzed on agarose gels for cor-
rect size and the presence of a single reaction product. For two-step qPCR,
the mRNA was first reverse-transcribed using the same RT but at 25 °C for 10
min followed by 42 °C for 60 min. The cDNA was then diluted, and qPCR was
performed (40 cycles of 95 °C for 15 s and 60 °C for 1 min). Resulting cycle
threshold (Ct) values were normalized to Rn18s, and the ΔΔCt method was
then used to express values as fold-over control samples. All samples were
run in at least duplicates, and statistical analysis was performed on 2−(ΔCt)
values. The primer sequences used can be obtained on request.
Western Blot Analysis and Immunohistochemistry. For protein analysis, total
cell lysates (10–50 μg) were loaded onto SDS/PAGE gels, separated, and
transferred onto nitrocellulose membranes. Detection was accomplished by
using the following primary antibodies: ACSL1 antibody (rabbit polyclonal
#4047, 1:1,000 dilution; Cell Signaling Technology), β-actin antibody (mouse
monoclonal, 1:10,000 dilution; Sigma-Aldrich), p-JNK Thr183/Tyr185 anti-
body (mouse monoclonal #9255, 1:1,000 dilution; Cell Signaling), and total
JNK antibody (rabbit polyclonal #9252, 1:1,000 dilution; Cell Signaling). HRP-
conjugated secondary antibodies were used. In some experiments, macro-
phage cell membranes were isolated before Western blot analysis of ACSL1.
In short, membrane fractions were acquired by a low-speed centrifugation
followed by a high-speed centrifugation (5,000 × g for 2 min and 100,000 ×
g for 1 h at 4 °C, respectively). Supernatant and pellet were collected, re-
spectively. A Mac-2 antibody (rat monoclonal, clone M3/38, 1:1,000 dilution;
Cedarlane) was used as a loading control for membrane fractions.
Immunohistochemistry was performed on sections of BCA lesions adjacent
to the maximal lesion site. A rat monoclonal anti–Mac-2 antibody was used to
detect macrophages (22). A rabbit anti-PTGS2 polyclonal antibody (#4842,
1:200 dilution; Cell Signaling) was used to detect PTGS2-positive lesion cells,
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and a rabbit polyclonal anti-CCL2 antibody (ab7202, 1:500 dilution; abcam)
was used to detect CCL2-positive lesion cells. Both antibodies were used
after antigen retrieval in boiling 10 mM citric acid and 0.05% Tween 20
buffer (pH 6.0) and a subsequent 30-min incubation in a Styrofoam box.
Negative control antibodies were of the same subclass and concentration as
the primary antibodies.
Analysis of Plasma Membrane-Associated ACSL1 by MS. Cell surface-associated
proteins were isolated from mouse or human macrophages using bio-
tinylation. After M1 or M2 activation, or no activation, of mouse and human
macrophages, cell surface-associated proteins were isolated using the Pin-
point Cell Surface Protein Isolation Kit (product #89881; Pierce Bio-
technology) according to the manufacturer’s protocol. Briefly, cells were
washed with ice-cold PBS and biotinylated for 30 min at 4 °C with gentle
shaking. After quenching the reaction, the cells were washed with Tris-
buffered saline (pH 7.2) containing 200 mM glutathione disulfide, and cel-
lular lysates were prepared by sonication. Biotin-labeled proteins were iso-
lated with NeutrAvidin (Pierce Biotechnology) resin. Eluted proteins were
alkylated and digested overnight at 37 °C with sequencing-grade trypsin
(1:50, wt/wt, trypsin/protein; Promega). Analysis of ACSL1-specific peptides
was performed by LC-ESI-MS/MS as previously described (22). MS/MS spectra
were searched against the mouse International Protein Index database
(version ipi.MOUSE.fasta.20071030) or the human database (ipi.HUMAN.
fasta.20100406) using the SEQUEST search engine with the following search
parameters: unrestricted enzyme specificity, 3.0 atomic mass units (amu)
precursor ion mass tolerance, 1.0 amu fragment ion mass tolerance, fixed
Cys alkylation, and variable Met oxidation. ACSL1-specific peptides detected
by LC-ESI-MS/MS were quantified by spectral counting (the total number of
unique MS/MS spectra detected for ACSL1).
Lipid Mediator Lipidomics. Samples consisting of macrophages and the con-
ditioned media combined were analyzed using an ABI Sciex Instruments 3200
Q-trap LC/MS/MS system equipped with a TurboV ionization source with
a turbo ion spray probe. After solid-phase extraction (39), samples were
suspended in mobile phase and injected into the HPLC component, which
consisted of a Shimadzu LC20AD gradient pump with an Aglient Eclipse plus
C18 (50 × 4.6 mm, 1.8 μm) column (Agilent Technologies). The column was
eluted at a flow rate of 0.4 mL/min with methanol/water/acetic acid
(60:40:0.01, vol/vol/v) with a gradient increasing to 100% methanol from
0 to 13.5 min. Information-dependent acquisition (IDA) used multiple re-
action monitoring for each lipid mediator of interest with source parameters
set as follows: ion spray voltage, −4,000 V; curtain gas, 20 U; ion source gas
flow rates 1 and 2, 50 U each; temperature, 500 °C. IDA criteria were as
follows: the most abundant compound was chosen to fragment with no
exclusion of former target and above the threshold of 300 counts/s (cps). For
enhanced product ion collision, energy was set at −25 V, with a spread of −5
V and +5 V using dynamic fill time. The mass range was 100–400 m/z, with
a scan rate of 1,000 amu/s and a complete cycle (multiple reaction moni-
toring, IDA, and enhanced product ion) of ∼1 s. Lipid mediators prepared by
total organic synthesis (i.e., PD1, RvD1, and RvE1) or commercial synthetic
standards (i.e., PGs and LTB4 from Cayman Chemical) were used to obtain
calibration curves for quantitation. Deuterium-labeled eicosanoids d8-5S-
HETE and d4-PGE2 were used as internal standards.
Bone Marrow Transplants and Atherosclerosis Studies. Female LDLR−/−;GP+
mice (12–14 wk old) received i.v. bone marrow transplants from either WT or
ACSL1M−/− mice (5 × 106 cells; purified of erythrocytes) after lethal irradia-
tion (10 Gy). For isolation of peritoneal macrophages, the mice were allowed
to recover for 3–7 wk, and they were then switched to a low-fat semipurified
diet (10) and maintained for an additional 4 wk. LDLR-deficient mice were
used as recipients, because these mice have higher plasma lipid levels and
thus, better mimic the atherosclerosis studies than C57BL/6 mice. For studies
of diabetes-accelerated atherosclerosis, bone marrow-transplanted mice
were allowed to recover for 3 wk, injected with LCMV or saline, and 1 wk
after injection, switched to a low-fat semipurified diet and maintained for
an additional 12 wk. Some nondiabetic mice were maintained for 20 wk.
Body weights, blood glucose, and blood cholesterol were determined every
3–4 wk for the nondiabetic mice and more frequently if needed for diabetic
mice. At the end of the study, mice were perfusion-fixed under physiological
pressure (10). The BCA was dissected, embedded, and serial sectioned. Every
fourth section was stained using a Movat’s pentachrome stain procedure as
described previously (22), and adjacent sections were used for immunohis-
tochemistry. Maximal lesion areas were determined by an investigator in
a masked fashion. In addition, the aortic arch and thoracic aorta (to the first
intercostal artery) were dissected and stained using Sudan IV to assess en
face lesion area (10). All animal studies were approved by the Institutional
Animal Care and Use Committee at the University of Washington.
Statistical Analyses. Statistical analysis was performed using two-tailed un-
paired Student t test, one- or two-way ANOVA with appropriate posthoc
tests, or Fisher exact test. Probabilities of less than 0.05 were considered
statistically significant. In vitro experiments were performed at least three
times in independent experiments.
Additional Methods. Additional methods are described in SI Materials
and Methods.
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